Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,123 people get MDVN articles and Market Currents by email alert.

Get email alerts on MDVN »

MDVN

Medivation, Inc.

5/23/2013, 4:57 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 5:27 PM More on Medivation (MDVN): Q1 beats on all fronts as per share losses came down and revenue went up. Net sales of Xtandi, as reported by partner Astellas, were $75.4M, a threefold increase over the prior quarter. The company says it continues to expect total operating expenses for 2013 to be between $285M and $300M. Shares -1% AH. Comment! [Healthcare, Earnings]
Thursday, May 9, 4:13 PM Medivation (MDVN): Q1 EPS of -$0.36 beats by $0.02. Revenue of $46.15M beats by $7.61M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
Wednesday, March 6, 8:51 AM SA Author Amit Cohen of Biomed Group delves into the strong initial sales of Medivation's (MDVN) Xtandi treatment for prostate cancer, which was launched in the U.S. in September. Q4 revenues of the drug were $57.4M, while those of J&J's (JNJ) rival product Zytiga fell 16% sequentially. Although Xtandi is more expensive, it has a "number of advantages" over Zytiga. Comment! [Healthcare, Quick Ideas]
Friday, March 1, 2:07 PM Medivation (MDVN -7%) slides today, despite posting a better than expected Q4 result yesterday. Collaboration revenue was $37.2M, more than the $34.4M in Q4 revenue analysts had expected. For FY13 the company expects operating expenses net of cost-sharing payments from Astellas, to be between $285M and $300M, approximately $29M of which consists of non-cash stock-based compensation expense. The company continues to expect approximately $7M in capital expenditures in 2013. Comment! [Healthcare, Earnings, On the Move]
Thursday, February 28, 4:15 PM Medivation (MDVN): Q4 EPS of -$0.43 beats by $0.09. Revenue of $57.4M beats by $23.04M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 28, 12:10 AM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU Comment! [Earnings]
Wednesday, February 27, 5:35 PM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU 1 Comment [Earnings]
Wednesday, February 13, 12:59 PM Medivation (MDVN +1.2%) gains today after presenting data for its monotherapy enzalutamide, showing it's treatment on prostate cancer has positive results. The study showed that the treatment increased serum testosterone by a mean of 114% at week 25 as compared to its baseline, and the median change in PSA was -99.6%. 1 Comment [Healthcare, On the Move]
Friday, February 1, 12:20 PM Medivation (MDVN +3.4%) moves up today after its Japanese alliance partner Astellas Pharma reported in its financial results last night that it expects Xtandi sales to exceed year-end net sales targets ending on March 31. MDVN is due to report at the end of February. Separately, Jefferies raises its price target on the shares from $62 to $64. Comment! [Healthcare, On the Move]
Monday, December 24, 2012, 11:59 AM Medivation (MDVN -5.7%) spikes lower after a California Superior Court rejected it's contention that UCLA had violated its agreements with the company by licensing certain compounds to another drug company, Aragon. The court found that the licensing deal did not prohibit the school from granting rights to Aragon for compounds that were discovered prior to those licensed to MDVN. Aragon is using the compounds to develop a drug, ARN-509, which could compete with Medivation's Xtandi, a prostate cancer treatment already approved by the FDA. Comment! [Healthcare, On the Move]
Friday, November 9, 2012, 4:16 PM Medivation (MDVN): Q3 EPS loss of $0.06 misses by $0.02. Revenue of $64.8M beats by $16M. (PR) Shares -1% AH.
Comment! [Earnings, On the Move]
Friday, November 9, 2012, 12:05 AM Notable earnings after Friday’s close: HUSA, MDVN, XIDE Comment! [Earnings]